Celix Pharmaceuticals
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • About us
  • Team
  • Products
  • Business Development
  • Sustainability
  • News
  • Careers
  • Contact us
  • More
    • About us
    • Team
    • Products
    • Business Development
    • Sustainability
    • News
    • Careers
    • Contact us
Celix Pharmaceuticals

Signed in as:

filler@godaddy.com

  • About us
  • Team
  • Products
  • Business Development
  • Sustainability
  • News
  • Careers
  • Contact us

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

14th February 2022

Celix Pharma is pleased to announce its partners’ approval of their Marketing Authorisation (MA) for Fesoterodine fumarate 4mg and 8mg prolonged-release tablets.  


Fesoterodine fumarate is indicated in adults for treatment of the symptoms associated with overactive bladder, a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination. Fesoterodine belongs to a class of medications called antimuscarinics, which work by relaxing the bladder muscles (1). 


“Fesoterodine is an important product in our portfolio with a commercial launch scheduled for Qtr 2 this year, post expiry of the relevant patents, launching first in Celix livery under partners MA, and switching to Celix MA post launch” – Subir Kohli, Co-founder & CEO. 


Commenting on the approval, Shantreddy, Co-founder & COO states “As a prolonged-released tablet, Fesoterodine is a challenging development and we are pleased to have successfully navigated all hurdles to obtain this MA”.     






(1) Source: MedlinePlus (https://medlineplus.gov/druginfo/meds/a609021.html/) 

About Celix Pharma Ltd 

Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries with a portfolio spanning generics, value-added generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially led, customer-focused organization supported with strategic partnerships in R&D and manufacturing. 


 For more information, visit www.celixpharma.com  

Follow us on Linkedin

Copyright © 2020 Celix Pharma Ltd.

Company No. 12474195 (Registered in England & Wales)

All Rights Reserved.

  • Privacy Policy

Powered by

Cookie Policy

This website uses cookies. By continuing to use this site, you accept our use of cookies. Privacy Policy

Accept & Close